They all represent potential new therapies for the treatment of MLL leukemia, as they have demonstrated modulation of the expression of HOXA9 and MEIS1 in human MLL-r leukemic cell lines (MV-4-11 or MOLM13) and a substantial survival benefit in MLL-r leukemia model mice, through the promotion of hematopoietic cell lineages differentiation, reaching complete remission of leukemia. Here, HOXA9 is linked to leukemia.